DIMENSIONAL FUND ADVISORS LP - DECIPHERA PHARMACEUTICALS IN ownership

DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 165 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.08 and the average weighting 0.4%.

Quarter-by-quarter ownership
DIMENSIONAL FUND ADVISORS LP ownership history of DECIPHERA PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$18,689,093
-5.8%
1,469,244
+4.3%
0.01%0.0%
Q2 2023$19,830,266
-6.4%
1,408,514
+2.7%
0.01%
-14.3%
Q1 2023$21,193,771
+119984.8%
1,371,796
+27.4%
0.01%
+40.0%
Q4 2022$17,649
-99.9%
1,076,809
+2.8%
0.01%
-28.6%
Q3 2022$19,379,000
+84.7%
1,047,533
+31.3%
0.01%
+75.0%
Q2 2022$10,491,000
+283.6%
797,756
+170.4%
0.00%
+300.0%
Q1 2022$2,735,000
-5.9%
295,019
-0.8%
0.00%0.0%
Q4 2021$2,907,000
-60.8%
297,545
+36.3%
0.00%
-50.0%
Q3 2021$7,420,000
+109.9%
218,353
+126.1%
0.00%
+100.0%
Q2 2021$3,535,000
-20.6%
96,553
-2.4%
0.00%0.0%
Q1 2021$4,453,000
+33.3%
98,974
+69.1%
0.00%0.0%
Q4 2020$3,340,000
+7.7%
58,527
-3.2%
0.00%0.0%
Q3 2020$3,100,000
-88.8%
60,431
-87.0%
0.00%
-91.7%
Q2 2020$27,752,000
-0.5%
464,702
-31.4%
0.01%
-20.0%
Q1 2020$27,901,000
-32.4%
677,686
+2.3%
0.02%0.0%
Q4 2019$41,249,000
+95.6%
662,734
+6.6%
0.02%
+87.5%
Q3 2019$21,092,000
+96.0%
621,503
+30.3%
0.01%
+100.0%
Q2 2019$10,759,000
+22.0%
477,049
+25.5%
0.00%0.0%
Q1 2019$8,822,000
+103.4%
380,040
+83.9%
0.00%
+100.0%
Q4 2018$4,337,000206,6150.00%
Other shareholders
DECIPHERA PHARMACEUTICALS IN shareholders Q3 2020
NameSharesValueWeighting ↓
New Leaf Venture Partners, L.L.C. 1,209,571$11,213,0005.53%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5,580,456$51,731,0001.16%
ARMISTICE CAPITAL, LLC 5,836,000$54,100,0001.05%
Pinz Capital Management, LP 165,835$1,537,0000.96%
Sunesis Advisors, LLC 96,299$893,0000.52%
Redmile Group, LLC 664,817$6,163,0000.19%
PDT Partners, LLC 222,343$2,061,0000.18%
Bayesian Capital Management, LP 41,900$388,0000.06%
Laurion Capital Management LP 459,290$4,258,0000.05%
Hennion & Walsh Asset Management, Inc. 101,643$942,0000.05%
View complete list of DECIPHERA PHARMACEUTICALS IN shareholders